Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
Information source: H. Lundbeck A/S
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depressive Disorder
Intervention: Placebo (Drug); Vortioxetine (Lu AA21004) (Drug); Venlafaxine XL (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: H. Lundbeck A/S Official(s) and/or principal investigator(s): Email contact via H. Lundbeck A/S, Study Director, Affiliation: LundbeckClinicalTrials@lundbeck.com
Summary
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and
tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive
Disorder (MDD).
Clinical Details
Official title: Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Change From Baseline in MADRS Total Score After 6 Weeks of Treatment
Secondary outcome: Change From Baseline in MADRS Total Score After 1 Week of TreatmentChange From Baseline in HAM-D 24 Total Score After 6 Weeks of Treatment Change From Baseline in HAM-A Total Score After 6 Weeks of Treatment Change From Baseline in CGI-S Score After 6 Weeks of Treatment Change in Clinical Status Using CGI-I Score at Week 6 Proportion of Responders at Week 6 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline) Proportion of Remitters at Week 6 (Remission is Defined as a MADRS Total Score <=10)
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- MDE as primary diagnosis according to DSM-IV-TR criteria (classification code 296. xx)
- Current MDE duration of at least 3 months and less than 12 months
- The patient has a MADRS total score >=30
Exclusion Criteria:
- Any current psychiatric disorder other than MDD as defined in the DSM-IV TR
- Any substance disorder within the previous 6 months
- Female patients of childbearing potential who are not using effective contraception
- Use of any psychoactive medication 2 weeks prior to screening and during the study
Other protocol-defined inclusion and exclusion criteria may apply.
Locations and Contacts
Additional Information
Starting date: August 2006
Last updated: April 22, 2014
|